Genertec Universal Medical Group Company Limited Return on Equity

Genertec Universal Medical Group Company Limited (UMTAF) currently reports a ROE of 21.13%. That is above the sector sector average of 11.64%. Use the charts on this page to explore Genertec Universal Medical Group Company Limited's ROE history and peer comparisons.

Genertec Universal Medical Group Company Limited's ROE of 21.13% is higher than the its sector sector average of 11.64%. That is roughly 81.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Genertec Universal Medical Group Company Limited's current 21.13% should be judged against industry norms (sector average: 11.64%) and against UMTAF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 21.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Genertec Universal Medical Group Company Limited, and consider following UMTAF for alerts when major investors trade the stock.